Sysmex (TSE:6869) Could Be 30% Undervalued Following Raised Earnings Guidance

Sysmex (TSE:6869) lifted its earnings guidance for the six months to September 2026 and the full year to March 2027, citing stronger hematology instrument sales in the Americas and favorable yen depreciation.

See our latest analysis for Sysmex.

The improved guidance appears to have fed into sentiment around Sysmex, with the stock showing strong short term momentum. The 7 day share price return of 16.17% and 90 day share price return of 38.87% contrast with a 5 year total shareholder return that declined 47.84%. This points to a recent shift in how the market is weighing its prospects and risks.

If stronger earnings guidance in healthcare gets you thinking about where else growth stories might emerge next, it can be useful to scan beyond a single stock. You can use this as a springboard to look at other companies in related areas of medical technology and automation by checking the 37 robotics and automation stocks

Sysmex’s sharp rebound sits between two stories. One says earnings guidance and currency benefits reveal a healthier business; the other says sentiment has simply swung too far. How does the current valuation line up with that trade off?

Most Popular Narrative: 30.2% Undervalued

At a last close of ¥1,918.5 versus a narrative fair value of ¥2,746.86, Sysmex is framed as materially undervalued, with that gap hinging on a specific growth and margin path.

Expansion in the Americas and EMEA, including growing placements in hemostasis and hematology and an emerging phase where higher margin reagent sales follow installed equipment, supports a mix shift that can lift revenue and operating margins over time.

Read the complete narrative. Read the complete narrative.

Want to see what sits behind that valuation gap for Sysmex? The narrative leans heavily on compounding revenue, rising profitability and a future earnings multiple that assumes real staying power.

Result: Fair Value of ¥2,746.86 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Sysmex’s bullish narrative still faces real tests, particularly around ongoing healthcare cost controls in China and the risk that higher global investment fails to scale earnings as expected.

Find out about the key risks to this Sysmex narrative.

Another View On Sysmex Using Market Multiples

The fair value estimate of ¥2,746.86 presents Sysmex as undervalued. However, the current P/E ratio of 29.3x tells a different story, as it is higher than the JP Medical Equipment industry at 16.4x, peers at 21.7x, and even above a fair ratio of 26.8x that the market could move toward over time. For investors, that gap suggests less room for error if earnings or sentiment slip again.

To see how this pricing stack compares in more detail, and what the numbers imply for potential upside or downside risk, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mixed signals around Sysmex leave you unsure, treat that as a prompt to check the numbers yourself and move quickly to your own stance using the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond Sysmex?

If Sysmex has sharpened your focus on valuations and risk, now is the time to widen your watchlist and spot other opportunities before the crowd catches up.

• Target dependable cash flows by scanning companies with healthy finances using the solid balance sheet and fundamentals stocks screener (40 results).
• Hunt for potential mispriced opportunities by reviewing the 24 high quality undervalued stocks.
• Prioritise stability and income potential by shortlisting stocks in the 33 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com